Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Squamous Cell Carcinoma of Head and Neck 2Osteosarcoma 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Pathologic Complete Response 1Neutropenia 1Neoplasms 1NSCLC 1Myelosuppression 1Hemangiosarcoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Advanced Squamous Non-Small-Cell Lung Cancer 1

Interventions

trilaciclib 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Myelosuppression × trilaciclib × Clear all
NCT06490081 2024-09-24

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
40 enrolled

Myelosuppression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡